Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 352

i2x identifies MS&AD for $11.4m round

MS&AD Ventures has contributed to a round for i2x, which offers an enhanced speech recognition product that provides automated coaching tips to improve business phone calls.

Feb 28, 2019

i2x identifies UVC Partners for $11.4m round

Unternehmertum’s VC affiliate co-led the deal for i2x, which offers an enhanced speech recognition product that provides automated coaching tips to improve business phone calls.

Feb 28, 2019

CCS connects to Adtran for $10m

Touchstone Innovations-backed Cambridge Communication System has received $10m in a funding round that included a $5m commitment from Adtran.

Feb 28, 2019

Birmingham unis call angel network

University of Birmingham and Aston University have deepened their relationship with Warwick-operated Minerva to start a syndicate targeting businesses in the West Midlands.

Feb 28, 2019

CCS connects to Adtran for $10m

Cambridge Communication System has received $10m in a funding round that included a $5m commitment from Adtran.

Feb 28, 2019

Aidence detects Rabobank for series A

Rabo Ventures has co-led the artificial intelligence-based medical imaging technology developer's $11.3m series A alongside Inkef Capital.

Feb 28, 2019

Yukin yields Satt Sud-Est licences

Satt Sud-Est has licensed Yukin Therapeutics to commercialise patents originating from several French institutions on the back of inventions from regional research hub Canceropôle Provence-Alpes-Côte d'Azur.

Feb 28, 2019

OSI welcomes Conn and Pichette

Charles Conn and Patrick Pichette will join Oxford Sciences Innovation to become chief executive and chairman, respectively, with founder Dave Norwood retiring.

Feb 28, 2019

Hookipa Pharma develops series D

Immunotherapy developer Hookipa, backed by Gilead, Boehringer Ingelheim and Takeda, has collected $37.5m in a series D round led by Redmile Group.

Feb 27, 2019

Anaveon validates Novartis for series A

Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.

Feb 27, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here